Treating Acute Leukemias
in Europe
Bridging Science and Practice: From Newest Clinical Approaches to Real-World Clinical Cases
Overview
This 3-hour virtual meeting will bring together leading experts to review the latest advances in adult acute lymphoblastic leukemia (ALL), including a preview of anticipated practice-changing data and key developments expected at ASH 2026. Through expert presentations, case-based discussions, and interactive faculty panels, participants will explore prognostic markers, frontline and relapsed/refractory treatment strategies, and the evolving roles of CAR-T therapy, bispecific antibodies, and transplantation. The program is designed to translate emerging science into practical clinical insights that can enhance treatment decision-making and improve patient outcomes across Europe.
Date and Location
23 November 2026
Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty
Josep-Maria Ribera, MD, PhD
Catalan Institute of Oncology, Badalona, Spain
Nicolas Boissel, MD
Saint-Louis Hospital, Paris, France
|
Agenda |
23 November 2026
17:30 – 20:30 (CET)
| Time (CET) | Topic | Presenter |
| 17:30 –17:35 | Welcome and meeting overview; introduction to the voting system | Elias Jabbour, MD |
| 17:35 –18:00 | Latest Achievements and Developments in ALL: Key Advances, Emerging Data, and What to Expect at ASH 2026 | Elias Jabbour, MD |
| 18:00 –18:20 | Review of Prognostic and Predictive Markers in ALL | TBC |
| 18:20 –18:45 | First-Line Treatment Best Practices in ALL: Optimizing Care Across Ph+, AYA, and Older Patients, Including Expected ASH 2026 Frontline Updates | TBC |
| 18:45 –19:10 | Relapsed/Refractory (R/R) ALL: Treatment Strategies Across Ph−, and Ph+, and the Evolving Role of Transplantation in Europe, Including Expected ASH 2026 R/R Updates | TBC |
| 19:10 –19:20 | Break | |
| 19:20 –19:35 | Patient Case 1: ALL Case-Based Panel | TBC |
| 19:35 –19:50 | Patient Case 2: ALL Case-Based Panel Discussion for R/R ALL | TBC |
| 19:50 –20:25 | Panel Discussion: Optimizing Treatment Pathways in Adult ALL | TBC |
| 20:25 –20:30 | Session Close | Elias Jabbour, MD |
